Recent Updates
Recently added Catalysts
CORT Positive Sentiment Score: 75/100

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

Wednesday, July 29, 2026 1 min read
Key Takeaway: Corcept Therapeutics reported strong financial results for the second quarter of 2026, highlighting the success of its oncology and Cushing's syndrome segments. The company continues to focus on developing medications that modulate cortisol effects for various severe disorders. This positive performance reflects the company's growth and market presence.

Market Sentiment Analysis

POSITIVE FACTORS

  • Strong financial results in oncology and Cushing's syndrome businesses.
  • Continued progress in the development of cortisol-modulating medications.

Full Press Release Details

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2026. Financial Results “Our oncology and Cushing’s syndrome businesses delivered strong results in the second quarter. In our oncology busi

Frequently Asked Questions

What were Corcept's financial results for Q2 2026?

Corcept Therapeutics reported strong financial results for the second quarter of 2026.

Which segments performed well for Corcept in Q2?

The oncology and Cushing's syndrome segments delivered strong results.

What is Corcept Therapeutics focused on developing?

The company is engaged in developing medications that modulate cortisol effects.

Tags: CORT Viatris Investor Conferences Healthcare Corcept Therapeutics financial results oncology Cushing's syndrome
Last updated: Jul 29, 2026

Biotech snapshot

Cash runway
$338M liquidity · $6M/mo burn
~58 mo
Minimal dilution risk
Lead asset
mifepristone + fluvastatinPhase 1
Healthy Subjects →

Catalyst track record

+186%
best trade around CORT's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for CORT.

See every catalyst's timing & PoA →